Dainippon Sumitomo - Acquiring Boston Biomedical - Hitting Two Birds with One Stone!
Dainippon Sumitomo Pharma (DSP) makes a major strategic move by acquiring Boston Biomedical for $200m upfront payment. At first sight, DSP acquires an advanced onco thx platform along with two novel molecules, but the implications cover a wide range of objectives.
This report analyzes rationale of the acquisition, potential future benefits to the DSP, fundamentals of cancer stem cell therapy and the financial implications.
This report analyzes rationale of the acquisition, potential future benefits to the DSP, fundamentals of cancer stem cell therapy and the financial implications.
COMPANIES MENTIONED
Dainippon Sumitomo
Dainippon Sumitomo
